MedTrace Logo

Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis

NCT04582084 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 583

Last updated 2020-10-19

No results posted yet for this study

Summary

In this open-label, multi-center, observational, post-marketing surveillance study, patients with ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly in real-world settings. Safety and effectiveness of biosimilar etanercept were evaluated in study participants for a duration of up to 12 months.

Conditions

Interventions

DRUG

Etanercept

Patients received biosimilar etanercept 25 mg twice weekly or 50 mg once weekly.

Sponsors & Collaborators

  • AryoGen Pharmed Co.

    lead INDUSTRY

Principal Investigators

  • Ahmadreza Jamshidi · Rheumatology Research Center, Tehran University of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-04
Primary Completion
2018-03-19
Completion
2018-03-19

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04582084 on ClinicalTrials.gov